




The relative strengths and weaknesses of Esperion Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 4.4% points. The greatest weakness of Esperion Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 148% points.

The company's Economic Capital Ratio, given in the ranking table, is 93%, being 152% points below the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	246,683	Assets	247,939
Cost of Goods Sold	0	Liabilities	571,717
Intangible Assets	56	Expenses	311,786
Liabilities, Current	92,308	Revenues	75,475
Liabilities, Non-Current	665	Stockholders Equity	-323,778
Other Assets	1,036	Net Income	-233,659
Other Compr. Net Income	29	Comprehensive Net Income	-233,644
Other Expenses	83,777	BaseVar	604,799
Other Liabilities	478,744	ECR before LimitedLiability	-229%
Other Net Income	2,652	Economic Capital Ratio	93%
Other Revenues	75,475		
Property and Equipment	164		
Research and Development	118,927		
Selling, General and Administrative Expense	109,082		